Welcome to our dedicated page for Sensus Healthcare SEC filings (Ticker: SRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sensus Healthcare, Inc. (Nasdaq: SRTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical device manufacturer focused on superficial radiotherapy (SRT and IG-SRT) for skin cancer and keloids, Sensus uses these filings to report material events, financial results and governance changes.
Recent Form 8-K filings describe quarterly financial results, where Sensus discusses revenue, unit shipments of SRT systems, Fair Deal Agreement treatment volumes, and the use of non-GAAP metrics such as Adjusted EBITDA. Other 8-Ks outline board developments, including the appointment of independent directors and related committee assignments, with the company noting compliance with Nasdaq independence standards.
Through its SEC reports, Sensus Healthcare also furnishes earnings press releases that include reconciliations between GAAP and non-GAAP financial measures, along with commentary on reimbursement milestones. For example, the company has highlighted the establishment of dedicated CPT codes by the Centers for Medicare & Medicaid Services for superficial radiotherapy used in non-melanoma skin cancer, which it views as important to its commercial strategy.
On Stock Titan, AI-powered tools can help readers interpret these filings by summarizing complex sections, highlighting key figures and pointing out notable changes from prior periods. Users can quickly identify items related to results of operations, board appointments, and other material events, and use the filings archive to follow how Sensus Healthcare’s financial profile and corporate governance have developed over time.
Sensus Healthcare is asking stockholders to vote at its 2026 Annual Meeting on May 29, 2026 in Boca Raton. Holders of 16,462,059 common shares as of April 10, 2026 may vote to elect two Class II directors through 2029, approve an advisory say‑on‑pay resolution, and ratify Carr, Riggs & Ingram, LLC as auditor for 2026.
The proxy details board structure, committee memberships and director independence, as well as 2025 pay for key executives, including a $600,000 base salary and total compensation of $1,417,860 for CEO Joseph C. Sardano and $1,213,917 for President and General Counsel Michael Sardano. It also describes employment agreements, change‑in‑control severance and a clawback policy tied to accounting restatements, plus prior auditor changes and 2025 audit fees.
Sensus Healthcare director Eric Sachetta filed an amended Form 4 to correct previously reported holdings. The filing clarifies that his spouse holds 2,093 shares of Sensus Healthcare common stock indirectly attributed to him. Earlier Forms 4 had inadvertently omitted these indirectly owned shares, and this amendment updates the reported ownership without reflecting any new buy or sell transaction.
Sensus Healthcare, Inc. chief financial officer Javier Rampolla reported a routine share adjustment linked to equity compensation. On July 21, 2022, 3,935 shares of common stock were withheld at $10.51 per share to cover his tax obligation from vested restricted stock. After this withholding, he beneficially owned 48,114 shares of common stock directly. The amended filing also corrects an earlier Form 4 that had overstated his holdings by 742 shares, revising the previously reported 48,856 shares to the accurate 48,114 shares as of that date.
Sensus Healthcare, Inc. executive Magdalena Martinez, the chief operating officer, filed an amended Form 3 to correct her reported share ownership. The original filing stated she held 18,000 shares of common stock, including restricted stock, but this amendment clarifies she actually held 12,754 shares as of January 3, 2023.
Sensus Healthcare, Inc. reported that Chief Operating Officer Magdalena Martinez had 741 shares of common stock withheld at $2.66 per share to satisfy withholding taxes arising from the vesting of restricted stock on December 19, 2023. After this tax-withholding disposition, she held 12,013 shares of common stock, including 7,500 shares of restricted stock, as of that date. The amended filing corrects a prior Form 4 that had understated her holdings as 9,759 shares.
Sensus Healthcare, Inc. provides non-invasive superficial radiation therapy systems to treat non-melanoma skin cancer and keloids, with 955 SRT units installed in 21 countries as of December 31, 2025. The company also offers service programs, revenue-share “Fair Deal” arrangements, financing solutions, and a new Sensus Link cloud platform.
In 2025 Sensus reported a net loss of $7.7 million after several profitable years, driven in part by reimbursement changes that affected sales. Research and development spending rose to $7.8 million, while regulatory compliance and quality expenses reached $3.4 million. A single U.S. customer represented 52% of 2025 revenue, highlighting concentration risk.
The company operates in a heavily regulated environment, with U.S. Class II devices cleared via the 510(k) pathway, extensive FDA and international oversight, and complex reimbursement rules including new superficial radiation CPT codes effective January 1, 2026. Sensus emphasizes protection of its eight global patents and multiple trademarks, ongoing cybersecurity initiatives, and compliance with healthcare fraud, abuse, and data privacy laws. It had 60 employees and an aggregate non-affiliate market value of $70,888,700 as of mid-2025.
Sensus Healthcare, Inc. director Eric Sachetta reported buying additional company shares in the open market. On this Form 4, he acquired 2,000 shares of common stock at an average price of $3.81 per share. After this transaction, his directly owned holdings increased to 142,113 common shares.
Sensus Healthcare, Inc. submitted a Form 3 identifying Larry Joseph Biscotti as a director-level reporting person. The insider data show no reported buy, sell, acquisition, or disposition transactions, and the transaction summary indicates neutral net activity with zero shares involved.
Sensus Healthcare reports fourth-quarter and full-year 2025 results, with revenues of $4.9 million for the quarter and $27.5 million for the year, both down sharply from 2024. The decline mainly reflects fewer systems sold and reduced sales to the company’s historically largest customer.
Fourth-quarter gross profit was $1.9 million, or 38.8% of revenues, and the company posted a net loss of $3.2 million, or $0.19 per share. For 2025, gross profit was $11.9 million, or 43.3% of revenue, with a net loss of $7.7 million, or $0.47 per share, compared with net income in 2024.
Management highlighted new dedicated CPT reimbursement codes for treating non-melanoma skin cancer with SRT, a more than 300% per-fraction increase versus the prior delivery code, stronger FDA program utilization, and meaningful international demand. Cash and cash equivalents were $22.1 million as of December 31, 2025, with no debt outstanding.
Sensus Healthcare, Inc. has changed its independent auditor following an acquisition of assets related to Berkowitz Pollack Brant Advisors + CPAs, LLP’s capital markets practice by Carr, Riggs & Ingram, LLC (CRI), effective January 1, 2026. On January 13, 2026, the Audit Committee dismissed Berkowitz Pollack Brant as the company’s independent registered public accounting firm and approved CRI as the new auditor.
Berkowitz Pollack Brant’s audit report on the company’s consolidated financial statements for the year ended December 31, 2024 contained no adverse opinion, no disclaimer of opinion, and was not qualified or modified. The company reports no disagreements with Berkowitz Pollack Brant on accounting, disclosure, or audit matters, and notes a previously disclosed material weakness in information technology general controls that was remediated as of December 31, 2024. The company also states it did not consult with CRI on accounting or audit issues before this appointment.